A Phase 4 interventional study of Desmopressin and Conditional alarm in Enuresis, Nocturnal, sponsored by University of Aarhus. Completed at 6 sites in 4 countries. Open to participants aged 6 Years to 14 Years. Per ClinicalTrials.gov, last updated 2023-08-02.
Sponsored by University of Aarhus · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing Deamino Arginine Vasopressin in Nocturnal Enuresis — 2 open to participants now, 2 under way, none of them phase 3. Deamino Arginine Vasopressin · Nocturnal Enuresis.
Among the 17 studies testing Deamino Arginine Vasopressin in Nocturnal Enuresis, this one is the 2nd largest by enrollment, is the only one that started in 2017, is one of 6 in phase 4, and was the 9th registered.
105 studies on the registry are indexed under Nocturnal Enuresis; 22 are open to participants now.
Browse Nocturnal Enuresis studies →2 of the 17 studies testing Deamino Arginine Vasopressin in Nocturnal Enuresis are open now, in 1 country. Recruiting first, the newest first:
Al-Azhar University · Sites in Egypt
Ages 7–14
Benha University · Sites in Egypt
Ages 5–15
By country, each count listing its studies:
Deamino Arginine Vasopressin: first FDA approval 1978 (DDAVP (NEEDS NO REFRIGERATION)). What it is approved for, and how studies give it, is on its page →
Of the 14 Nocturnal Enuresis studies recruiting now, 5 (36%) set no upper age limit and 9 (64%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.
This study: 6 Years to 14 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 324 is above the median of 66 across 77 interventional studies indexed under Nocturnal Enuresis.
Median enrollment 80 across the 17 interventional studies. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 17 have an industry lead sponsor. The 10 most frequent:
University of Aarhus is the lead sponsor of 1,300 studies on the registry; 189 are open to participants now.
University of Aarhus has 7 studies filed under Nocturnal Enuresis — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies testing Deamino Arginine Vasopressin in Nocturnal Enuresis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to investigate the importance of clinical characterization of children with monosymptomatic nocturnal enuresis (MNE) in order to improve treatment efficacy.
The hypothesis is that clinical characterization by measurement of nocturnal urine production and maximal voided volumes in children with MNE and subsequent treatment tailoring improves the response to first-line treatment approach.
This is a randomized, controlled study.
This study will be performed at Aarhus University Hospital (Denmark), Ghent University Hospital (Belgium) and Hospital of Zhengzhou University (China) following the same protocol.
According to the initial randomization, children will be allocated to treatment without (group A) or with (group B) prior clinical characterization based on home recordings.
Group A: The children will be randomized to either an enuresis alarm or desmopressin without evaluating the home recordings.
Group B: The home recordings will be evaluated and treatment will be based on the recordings. Desmopressin will be administered to the children with nocturnal polyuria and the conditional alarm to the children with reduced bladder capacity. Children with nocturnal polyuria and reduced bladder capacity will be treated with both desmopressin and conditional alarm. Children with neither nocturnal polyuria nor reduced bladder capacity will again be randomized to either desmopressin or alarm treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Children will receive desmopressin without evaluating the home recordings.
Drug: Desmopressin
Children will receive conditional alarm without evaluating the home recordings.
Device: Conditional alarm
Children with polyuria based on the home recordings will receive desmopressin.
Drug: Desmopressin
Children with reduced bladder capacity based on the home recordings will receive the conditional alarm.
Device: Conditional alarm
Children with polyuria and reduced bladder capacity based on the home recordings will receive desmopressin and the conditional alarm.
Drug: Desmopressin · Device: Conditional alarm
Children with neither nocturnal polyuria nor reduced bladder capacity based on the home recordings will be randomized to either desmopressin or alarm treatment. If there is no effect of the treatment, the treatment can be switched.
Drug: Desmopressin · Device: Conditional alarm
The children will be treated with 120 microgram/day the first two weeks. If the child is not completely dry, the dose will be increased to 240 microgram/day the rest of the study period (maximum eight weeks of treatment).
Also known as: Minirin, melt
Eight weeks of treatment.
The number of children who responded to the treatment
Evaluated by home recordings
Time frame: Eight weeks
The number of children achieving complete dryness (complete responders)
Evaluated by home recordings
Time frame: Eight weeks
Change in wet nights
Evaluated by home recordings
Time frame: Eight weeks
Plan to share: Yes
No publications or documents are linked to this record.
Ran from Oct 2017 to primary completion in Jan 2023, 63 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deamino Arginine Vasopressin